Background: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF). Trial Registration No: Eudract-Nr. 2016-002299-28 NCT02929329 ( Link Trial Status: recruitment stopped Enrolling Centers: worldwide, 8250 Patients randomized in Basel 14 Core Study Team:
© Christian Mueller, 2012 - 2024 │ DisclaimerImprintWebmaster │ Last Update: May 2024
Beate Hartmann Ph.D Sabrina Stefanelli Dr. Samyut Shrestha Cornelia Simmen Kristin Shrestha Claudia Stelzig